Vaccination With Tumor mRNA in Metastatic Melanoma - Fixed Combination Versus Individual Selection of Targeted Antigens

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

31

Participants

Timeline

Start Date

April 30, 2007

Primary Completion Date

August 31, 2011

Study Completion Date

December 31, 2012

Conditions
Malignant Melanoma
Interventions
BIOLOGICAL

mRNA coding for melanoma associated antigens

mRNA vaccine s.c. applied weekly

DRUG

GM-CSF

Given s.c. as adjuvant drug one day after vaccine

Trial Locations (1)

72076

Department of Dermatology, University of Tuebingen, Tübingen

Sponsors
All Listed Sponsors
collaborator

German Research Foundation

OTHER

lead

University Hospital Tuebingen

OTHER